The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
The transaction is expected to result in approximately $175 million to support further development of IMG-007
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Subscribe To Our Newsletter & Stay Updated
